{"id":"de-117-middle-dose-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Ocular discomfort"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ROCK inhibitors modulate the cytoskeleton of trabecular meshwork cells and endothelial cells lining Schlemm's canal, increasing conventional aqueous humor drainage and thereby lowering intraocular pressure. This mechanism differs from prostaglandin analogs and beta-blockers, offering a potential new therapeutic option for glaucoma and ocular hypertension.","oneSentence":"DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:31:33.605Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma or ocular hypertension (Phase 2)"}]},"trialDetails":[{"nctId":"NCT02179008","phase":"PHASE2","title":"Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2014-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":184},{"nctId":"NCT01868126","phase":"PHASE2","title":"Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2013-05","conditions":"Open-angle Glaucoma or Ocular Hypertension","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DE-117"],"phase":"phase_2","status":"active","brandName":"DE-117 Middle Dose ophthalmic solution","genericName":"DE-117 Middle Dose ophthalmic solution","companyName":"Santen Inc.","companyId":"santen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DE-117 Middle Dose ophthalmic solution is being studied in a clinical trial for the treatment of open-angle glaucoma and ocular hypertension. The study, NCT02179008, is a multi-center Phase II trial assessing the safety and efficacy of DE-117 Middle Dose ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}